Leigh Brody

Scripta Therapeutics is an Oxford-based techbio company that takes a biology-first approach to discover disease-modifying drugs that modulate transcription factor activity and reprogram biology. We aim to discover and develop therapeutics for neurodegenerative disorders. We are following a unique strategy, based on the concept that transcription factors, the master controllers of gene expression, are core drivers of disease and act as detailed and dynamic maps of disease. Therapeutics that modulate these maps to restore the healthy cell state can be efficiently identified by a data-rich, lab-in-the-loop combination of experimental biology with cutting-edge AI and informatics.

This is a catchall company for the doers, the thinkers, and the innovators.

Alma Angels is a diverse and active community with a bold mission: Generate $1 trillion in women-led wealth by 2050. Since 2020, we have brought together and trained over 500 angel investors who have invested into 200+ women (co)founders building tech or IP-rich ventures with global ambitions. These companies have gone on to raise more than £300m to date. Alma Angels is committed to training 10,000 angels and backing 10,000 women founders by 2035.

Scripta Therapeutics is an Oxford-based techbio company that takes a biology-first approach to discover disease-modifying drugs that modulate transcription factor activity and reprogram biology. We aim to discover and develop therapeutics for neurodegenerative disorders. We are following a unique strategy, based on the concept that transcription factors, the master controllers of gene expression, are core drivers of disease and act as detailed and dynamic maps of disease. Therapeutics that modulate these maps to restore the healthy cell state can be efficiently identified by a data-rich, lab-in-the-loop combination of experimental biology with cutting-edge AI and informatics.

This is a catchall company for the doers, the thinkers, and the innovators.

Alma Angels is a diverse and active community with a bold mission: Generate $1 trillion in women-led wealth by 2050. Since 2020, we have brought together and trained over 500 angel investors who have invested into 200+ women (co)founders building tech or IP-rich ventures with global ambitions. These companies have gone on to raise more than £300m to date. Alma Angels is committed to training 10,000 angels and backing 10,000 women founders by 2035.

AlbionVC backs Europe’s visionary founders solving the world’s hardest problems. We bring capital, know-how, and a shared ambition to win. With £1 billion in venture funds and conviction led investing across frontier technologies, our track record spans 100+ exits and early support for global champions such as Booking.com, Quantexa, Oviva, Elliptic and tem. From the first concept to global scale, we back founders bold enough to own the future.

Index Ventures partners with exceptional entrepreneurs – those with unique insight who are intrinsically driven to make their vision a reality. We help them turn their bold ideas into global businesses, and through the companies they build, have a long-lasting and positive impact on the world around us. Index-backed businesses are supported by an experienced team of investors, strategists, and an extensive global network built over three decades of startup investing. Working side-by-side through the scale up journey, we forge deep and long-lasting relationships with founders and their teams. The vast majority of these partnerships begin early in the company’s life, at Seed and Series A, and extend to IPO and beyond. Operating as one team, with feet firmly on both sides of the Atlantic – from London to Tel Aviv, and San Francisco to New York – we are an international team with a global mindset, with experience supporting founders wherever they emerge. When they succeed, they generate returns that in turn support Index’s investors, including non-profit foundations; education, healthcare and research endowments; and other impact-driven organizations.